S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NYSEAMERICAN:MTNB

Matinas BioPharma Stock Forecast, Price & News

$1.00
+0.07 (+7.55%)
(As of 12/6/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.87
$1.03
50-Day Range
N/A
52-Week Range
$0.67
$2.22
Volume
1.36 million shs
Average Volume
2.56 million shs
Market Capitalization
$215.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.21
30 days | 90 days | 365 days | Advanced Chart
Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.


Matinas BioPharma logo

About Matinas BioPharma

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Headlines

Pre-market Movers: GOVX, ITRM, GREE, RGS, MTNB…
September 29, 2021 |  markets.businessinsider.com
Matinas BioPharma Stock Jumps After Meningitis Candidate Data
September 13, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:MTNB
CIK
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Sales & Book Value

Annual Sales
$160 thousand
Book Value
$0.27 per share

Profitability

Net Income
$-22.45 million
Pretax Margin
-23,879.17%

Debt

Price-To-Earnings

Miscellaneous

Free Float
198,732,000
Market Cap
$215.60 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/07/2021
Today
12/06/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.63 out of 5 stars

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

Is Matinas BioPharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Matinas BioPharma stock.
View analyst ratings for Matinas BioPharma
or view top-rated stocks.

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) issued its quarterly earnings data on Sunday, November, 7th. The company reported ($0.03) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.01.
View Matinas BioPharma's earnings history
.

What price target have analysts set for MTNB?

4 Wall Street analysts have issued 12 month price targets for Matinas BioPharma's stock. Their forecasts range from $3.00 to $4.00. On average, they expect Matinas BioPharma's stock price to reach $3.33 in the next year. This suggests a possible upside of 234.3% from the stock's current price.
View analysts' price targets for Matinas BioPharma
or view top-rated stocks among Wall Street analysts.

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the following people:
  • Jerome D. Jabbour, President, Chief Executive Officer & Director
  • Keith A. Kucinski, Chief Financial Officer
  • Raphael J. Mannino, Chief Scientific Officer & Senior Vice President
  • James J. Ferguson, Chief Medical Officer
  • Hui Liu, Chief Technology Officer

What other stocks do shareholders of Matinas BioPharma own?

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sargent Investment Group LLC (1.51%), BlackRock Inc. (1.27%), Arkadios Wealth Advisors (0.65%), Geode Capital Management LLC (0.65%), GSA Capital Partners LLP (0.34%) and LPL Financial LLC (0.13%). Company insiders that own Matinas BioPharma stock include Adam K Stern, Jerome D Jabbour and Patrick G Lepore.
View institutional ownership trends for Matinas BioPharma
.

Which institutional investors are selling Matinas BioPharma stock?

MTNB stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Victory Capital Management Inc., Platform Technology Partners, WINTON GROUP Ltd, and MONECO Advisors LLC.
View insider buying and selling activity for Matinas BioPharma
or view top insider-selling stocks.

Which institutional investors are buying Matinas BioPharma stock?

MTNB stock was bought by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, Arkadios Wealth Advisors, Citadel Advisors LLC, Jane Street Group LLC, Moors & Cabot Inc., LPL Financial LLC, Private Advisor Group LLC, and Ropes Wealth Advisors LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, Jerome D Jabbour, and Patrick G Lepore.
View insider buying and selling activity for Matinas BioPharma
or or view top insider-buying stocks.

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $1.00.

How much money does Matinas BioPharma make?

Matinas BioPharma has a market capitalization of $215.60 million and generates $160 thousand in revenue each year. The company earns $-22.45 million in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does Matinas BioPharma have?

Matinas BioPharma employs 20 workers across the globe.

What is Matinas BioPharma's official website?

The official website for Matinas BioPharma is www.matinasbiopharma.com.

Where are Matinas BioPharma's headquarters?

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at (908) 443-1860 or via email at [email protected].


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.